EUVIMEDEUVIMED entdecken
Crossref

A SPECT-Guided, PET-Sparing Algorithm for PSMA Radiopharmaceutical Therapy Evaluation (SPARE)

Mutaz Kassas, Mourad Zekri, Raluca Poenaru, Paulus Kristanto, Ioannis Karfis, Patrick Flamen, Carlos Artigas

Journal of Nuclear Medicine · 12.11.2026 · jnumed.126.273398

DOI: 10.2967/jnumed.126.273398 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 12.11.2026. Verfasst von Mutaz Kassas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium; and. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

[177Lu]Lu-PSMA radiopharmaceutical therapy is delivered as repeated cycles, yet the decision to continue or adapt treatment after the second cycle is not standardized. Posttherapy SPECT/CT is routinely performed but rarely used formally for response assessment. We developed a multimodality, response-adapted algorithm applied after cycle 2 and tested its concordance with real-world decisions.

Methods

We studied 142 men with metastatic androgen pathway modulator-resistant prostate cancer (formerly metastatic castration-resistant prostate cancer) who completed at least 2 cycles of [177Lu]Lu-PSMA and underwent posttherapy SPECT/CT, baseline and 12-wk prostate-specific antigen (PSA) testing, and baseline and interim prostate-specific membrane antigen (PSMA) PET and [18F]FDG PET. Response was assessed in accordance with Prostate Cancer Working Group 4 recommendations for PSA and with RECIP 1.0 for SPECT and PSMA PET. The algorithm combined SPECT/CT and PSA, used PSMA PET only when both were stable, and yielded 3 recommendations: continue [177Lu]Lu-PSMA, discontinue [177Lu]Lu-PSMA, or consider [18F]FDG PET. The primary endpoints were the number of interim PSMA PET studies avoided and the concordance between algorithm recommendations (continue vs. discontinue) and real-world decisions. The secondary endpoint was intermodality response evaluation concordance.

Results

The algorithm recommended continuation in 74 patients (52.1%), discontinuation in 49 patients (34.5%), and [18F]FDG PET in 19 patients (13.4%). Interim PSMA PET/CT could be avoided in 120 patients (84.5%) (95% CI, 77.7%-89.5%). Among patients with a definitive recommendation, conditional agreement of the algorithm with real-world management decisions was 91.1% (95% CI, 84.7%-94.9%), with a κ of 0.81 (95% CI, 0.69-0.91). All 74 patients (100%) with an algorithm recommendation to continue treatment had matching real-world decisions for treatment continuation, whereas 38 (78%) of 49 patients with an algorithm recommendation to discontinue treatment had matching real-world decisions for treatment discontinuation. Response classification on SPECT agreed only moderately with PSA level (κ = 0.45) and PSMA PET (κ = 0.47), but the combination of SPECT and PSA raised agreement with PSMA PET to "substantial" (κ = 0.67), approaching that of PSMA PET with PSA level (κ = 0.70). Every discordant decision (n = 11) occurred when the algorithm recommended treatment discontinuation in a patient who nonetheless continued treatment, most commonly because [177Lu]Lu-PSMA was being used as a last line of therapy (7/11, 64%).

Conclusion

A SPECT-guided algorithm could have avoided most interim PSMA PET studies and reproduced real-world treatment decisions after 2 cycles of [177Lu]Lu-PSMA with high agreement. This algorithm may serve as the basis for a standardized treatment management framework, pending independent, prospective outcome-based validation.

Schlagwörter

Stichwörter der Autor:innen

Lu-PSMARECIPSPARESPECTresponse assessment

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium; and.
  • Data Centre, Unité de Gestion de L'Information, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
  • Department of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium; and carlos.artigas@hubruxelles.be.

Zitieren

APA

Kassas, M., Zekri, M., Poenaru, R., Kristanto, P., Karfis, I., Flamen, P., & Artigas, C. (2026). A SPECT-Guided, PET-Sparing Algorithm for PSMA Radiopharmaceutical Therapy Evaluation (SPARE). Journal of Nuclear Medicine, jnumed.126.273398. https://doi.org/10.2967/jnumed.126.273398

Vancouver

Kassas M, Zekri M, Poenaru R, Kristanto P, Karfis I, Flamen P, et al. A SPECT-Guided, PET-Sparing Algorithm for PSMA Radiopharmaceutical Therapy Evaluation (SPARE). Journal of Nuclear Medicine. 2026:jnumed.126.273398. doi:10.2967/jnumed.126.273398

BibTeX
@article{Kassas2026,
  author = {Kassas, Mutaz and Zekri, Mourad and Poenaru, Raluca and Kristanto, Paulus and Karfis, Ioannis and Flamen, Patrick and Artigas, Carlos},
  title = {A SPECT-Guided, PET-Sparing Algorithm for PSMA Radiopharmaceutical Therapy Evaluation (SPARE)},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  pages = {jnumed.126.273398},
  doi = {10.2967/jnumed.126.273398}
}
Kostenlos starten →